FLT3 and acute myeloid leukemia: These mutations can be subdivided into internal tandem duplicates (FLT3-ITD) and point mutations in the tyrosine kinase domain (FLT3-TKD), which are approximately 25% and 5% of the total AML, respectively [10,11].